Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to -$789000.0.

  • PROCEPT BioRobotics' Change in Account Payables fell 11519.06% to -$789000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 15123.59%. This contributed to the annual value of -$2.2 million for FY2024, which is 13717.4% down from last year.
  • Latest data reveals that PROCEPT BioRobotics reported Change in Account Payables of -$789000.0 as of Q3 2025, which was down 11519.06% from -$2.2 million recorded in Q2 2025.
  • Over the past 5 years, PROCEPT BioRobotics' Change in Account Payables peaked at $5.9 million during Q4 2023, and registered a low of -$5.4 million during Q4 2024.
  • For the 5-year period, PROCEPT BioRobotics' Change in Account Payables averaged around $480157.9, with its median value being $344000.0 (2024).
  • In the last 5 years, PROCEPT BioRobotics' Change in Account Payables tumbled by 281929.82% in 2021 and then surged by 372222.22% in 2024.
  • PROCEPT BioRobotics' Change in Account Payables (Quarter) stood at -$1.5 million in 2021, then skyrocketed by 81.68% to -$284000.0 in 2022, then skyrocketed by 2169.01% to $5.9 million in 2023, then plummeted by 191.54% to -$5.4 million in 2024, then soared by 85.33% to -$789000.0 in 2025.
  • Its Change in Account Payables stands at -$789000.0 for Q3 2025, versus -$2.2 million for Q2 2025 and $3.8 million for Q1 2025.